ChemoMetec AS (OCSE:CHEMM) Total Stockholders Equity: kr652.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:CHEMM ChemoMetec AS OCSE:CHEMM
98 GF Score
Price kr475.20
GF Value kr531.50
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ChemoMetec AS Total Stockholders Equity?

ChemoMetec AS OCSE:CHEMM -1.61% 98 Total Stockholders Equity is kr652.6 Mil as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 98/100 and a GF Value™ of kr531.50 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ChemoMetec AS's Total Stockholders Equity for the quarter that ended in Dec. 2025 was kr652.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ChemoMetec AS's Book Value per Share for the quarter that ended in Dec. 2025 was kr37.50. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ChemoMetec AS's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.01.

ChemoMetec AS  (OCSE:CHEMM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ChemoMetec AS's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(652.588-0)/17.402
=37.50

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ChemoMetec AS's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.355 + 2.856) / 652.588
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Total Stockholders Equity Related Terms

ChemoMetec AS Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Total Stockholders Equity Chart

ChemoMetec AS Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 264.98 357.21 533.04 565.32 673.36

ChemoMetec AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 498.73 565.32 597.98 673.36 652.59
OCSE:CHEMM
98GF Score
ChemoMetec AS OCSE:CHEMM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr652.6 Mil mean?
ChemoMetec AS (OCSE:CHEMM) has a Total Stockholders Equity of kr652.6 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ChemoMetec AS and its competitors.
Is ChemoMetec AS's Total Stockholders Equity too high?
ChemoMetec AS's current Total Stockholders Equity is kr652.6 Mil. Overall, ChemoMetec AS has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Total Stockholders Equity compare to ABT and SYK?
ChemoMetec AS's Total Stockholders Equity of kr652.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ChemoMetec AS and its competitors. ChemoMetec AS's current Total Stockholders Equity is kr652.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr531.50, compared to a current price of kr475.20 — trading 10.6% below its estimated fair value. The current Total Stockholders Equity is kr652.6 Mil. ChemoMetec AS's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Total Stockholders Equity is kr652.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr475.20 is trading 10.6% below its estimated GF Value™ of kr531.50. GuruFocus considers ChemoMetec AS to be Modestly Undervalued.

Key valuation signals for OCSE:CHEMM:

  • Total Stockholders Equity: kr652.6 Mil
  • GF Value™: kr531.50 vs. price of kr475.20 (10.6% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ChemoMetec AS Business Description

Other Exchanges CHEMMc:UK0DZ0:UKCHY:Germany
Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
98GF Score

Get the complete analysis for OCSE:CHEMM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr475.20
Price
kr531.50
GF Value